Business Context and Reporting Period
This Form 8-K Current Report was filed by Babcock & Wilcox Enterprises, Inc. on April 10, 2025, covering events occurring on April 4, 2025. The filing addresses a notice of potential delisting from the New York Stock Exchange (NYSE) due to low share price and the dismissal of the company's long-time auditor, Deloitte & Touche LLP, in favor of BDO USA, P.C.
Key Financial Metrics and Status
The filing does not provide specific revenue, profit, cash flow, or debt figures for the current period. However, it references the following financial conditions:
- Stock Price: The average closing price of common stock over the prior 30 trading days was below the $1.00 minimum required for NYSE listing.
- Going Concern: The previous auditor's report for the fiscal year ended December 31, 2024, included an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern.
- Internal Controls: The Company reported material weaknesses in internal control over financial reporting in its 2024 Form 10-K, affecting the control environment, risk assessment, control activities, information/communication, and monitoring activities.
Material Changes
- Listing Status: The Company received an NYSE Notice on April 4, 2025, indicating non-compliance with the minimum share price requirement. The stock will trade with a ".BC" designation during the six-month cure period.
- Auditor Change: Deloitte & Touche LLP, the auditor since 2014, was dismissed on April 4, 2025. BDO USA, P.C. was engaged as the new independent registered public accounting firm for the fiscal year ending December 31, 2025.
Outlook, Risks, and Management Commentary
Cure Period: The Company has six months from the date of the NYSE Notice to regain compliance. To do so, the stock must close at or above $1.00 and maintain a 30-day average closing price of at least $1.00 on the last trading day of any calendar month during this period.
Operational Impact: Management states the NYSE Notice has no immediate impact on listing status, ongoing business operations, SEC reporting requirements, or debt obligations.
Audit Transition: There were no disagreements with Deloitte regarding accounting principles or audit scope. The change in auditor was part of a competitive Request for Proposal (RFP) process for good corporate governance.
Investor Verification Checklist
- Verify the current stock price and 30-day average to assess the likelihood of regaining NYSE compliance within the six-month cure period.
- Review the "Going Concern" explanatory paragraph in the 2024 Form 10-K to understand the specific financial risks cited by the previous auditor.
- Examine the details of the material weaknesses in internal controls disclosed in the 2024 Form 10-K (Item 9A) to evaluate financial reporting reliability.
- Monitor future filings for the outcome of the auditor transition and any updates on the stock price cure plan.